MX2017013480A - Composicion farmaceutica para tratar y/o prevenir el cancer. - Google Patents
Composicion farmaceutica para tratar y/o prevenir el cancer.Info
- Publication number
- MX2017013480A MX2017013480A MX2017013480A MX2017013480A MX2017013480A MX 2017013480 A MX2017013480 A MX 2017013480A MX 2017013480 A MX2017013480 A MX 2017013480A MX 2017013480 A MX2017013480 A MX 2017013480A MX 2017013480 A MX2017013480 A MX 2017013480A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- cancer
- pharmaceutical composition
- treat
- protein
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102100028758 Chondroitin sulfate proteoglycan 5 Human genes 0.000 abstract 1
- 101000916485 Homo sapiens Chondroitin sulfate proteoglycan 5 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un objetivo de la presente invención es identificar una proteína de antígeno canceroso, específicamente expresada sobre la superficie de las células cancerosas, y proporciona el uso de un anticuerpo que se dirige a la proteína antigénica del cáncer, como un agente terapéutico y/o profiláctico para el cáncer. Una composición farmacéutica para tratar y/o prevenir el cáncer, que comprende un anticuerpo o un fragmento del mismo que tiene reactividad inmunológica con la proteína CSPG5, que consiste de cualquiera de las secuencias de aminoácidos representadas por las SEQ ID NOs: 8, 4, 6, 10 y 12, y una secuencia de aminoácidos que tiene una identidad de aminoácidos de 80% o más a la secuencia de aminoácidos, o un fragmento de la misma que consiste de 7 o más aminoácidos consecutivos, como un ingrediente activo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015093640 | 2015-04-30 | ||
| PCT/JP2016/063420 WO2016175307A1 (ja) | 2015-04-30 | 2016-04-28 | 癌の治療及び／又は予防用医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017013480A true MX2017013480A (es) | 2017-12-07 |
| MX380750B MX380750B (es) | 2025-03-12 |
Family
ID=57198482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013480A MX380750B (es) | 2015-04-30 | 2016-04-28 | Composición farmacéutica para tratar y/o prevenir el cáncer. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11129893B2 (es) |
| EP (1) | EP3290051B1 (es) |
| JP (1) | JP6862828B2 (es) |
| KR (1) | KR102729994B1 (es) |
| CN (1) | CN107530426A (es) |
| AU (1) | AU2016255255B2 (es) |
| BR (1) | BR112017022390A2 (es) |
| DK (1) | DK3290051T3 (es) |
| ES (1) | ES2762979T3 (es) |
| HU (1) | HUE047272T2 (es) |
| MX (1) | MX380750B (es) |
| PL (1) | PL3290051T3 (es) |
| PT (1) | PT3290051T (es) |
| RU (1) | RU2714205C2 (es) |
| WO (1) | WO2016175307A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3105000A1 (en) | 2018-06-26 | 2020-01-02 | Kyowa Kirin Co., Ltd. | Antibody binding to cell adhesion molecule 3 |
| EP3816291B1 (en) * | 2018-06-26 | 2025-12-31 | Kyowa Kirin Co., Ltd. | ANTIBODIES BINDING TO PROTEOGLYCAN-5 WITH CHONDROITINE SULFATE |
| CN111073889B (zh) * | 2019-12-20 | 2023-07-28 | 中国人民解放军第四军医大学 | 人cspg5基因的用途及相关产品 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| JPH09194502A (ja) * | 1995-11-13 | 1997-07-29 | Seikagaku Kogyo Co Ltd | 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体 |
| JP4315257B2 (ja) | 1995-11-13 | 2009-08-19 | 生化学工業株式会社 | 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体 |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| TWI390034B (zh) * | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
| CN101245386A (zh) * | 2008-03-26 | 2008-08-20 | 中南大学 | 用于多种肿瘤抑瘤基因检测的cDNA芯片 |
| PL2305300T3 (pl) | 2008-07-10 | 2016-09-30 | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
| PL2322221T3 (pl) | 2008-08-05 | 2015-01-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i zapobiegania raka |
| CA2767442A1 (en) | 2009-07-08 | 2011-01-13 | Actgen Inc. | Antibody having anti-cancer activity |
| JP2013013327A (ja) * | 2009-10-29 | 2013-01-24 | Actgen Inc | Ｍａｎｓｃ１蛋白質に結合し、抗癌活性を有する抗体 |
| JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
-
2016
- 2016-04-28 US US15/567,496 patent/US11129893B2/en active Active
- 2016-04-28 AU AU2016255255A patent/AU2016255255B2/en active Active
- 2016-04-28 PL PL16786583T patent/PL3290051T3/pl unknown
- 2016-04-28 KR KR1020177029174A patent/KR102729994B1/ko active Active
- 2016-04-28 MX MX2017013480A patent/MX380750B/es unknown
- 2016-04-28 EP EP16786583.1A patent/EP3290051B1/en active Active
- 2016-04-28 RU RU2017135005A patent/RU2714205C2/ru active
- 2016-04-28 WO PCT/JP2016/063420 patent/WO2016175307A1/ja not_active Ceased
- 2016-04-28 HU HUE16786583A patent/HUE047272T2/hu unknown
- 2016-04-28 JP JP2016539232A patent/JP6862828B2/ja active Active
- 2016-04-28 PT PT167865831T patent/PT3290051T/pt unknown
- 2016-04-28 DK DK16786583.1T patent/DK3290051T3/da active
- 2016-04-28 CN CN201680023169.6A patent/CN107530426A/zh active Pending
- 2016-04-28 BR BR112017022390-2A patent/BR112017022390A2/pt not_active Application Discontinuation
- 2016-04-28 ES ES16786583T patent/ES2762979T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2714205C2 (ru) | 2020-02-13 |
| PT3290051T (pt) | 2020-01-07 |
| EP3290051A4 (en) | 2018-12-05 |
| MX380750B (es) | 2025-03-12 |
| JPWO2016175307A1 (ja) | 2018-02-22 |
| AU2016255255A1 (en) | 2017-11-02 |
| JP6862828B2 (ja) | 2021-04-21 |
| ES2762979T3 (es) | 2020-05-26 |
| US20180085453A1 (en) | 2018-03-29 |
| KR20170141660A (ko) | 2017-12-26 |
| CA2983232A1 (en) | 2016-11-03 |
| US11129893B2 (en) | 2021-09-28 |
| EP3290051A1 (en) | 2018-03-07 |
| EP3290051B1 (en) | 2019-10-23 |
| WO2016175307A1 (ja) | 2016-11-03 |
| AU2016255255B2 (en) | 2021-07-22 |
| BR112017022390A2 (pt) | 2018-10-23 |
| RU2017135005A (ru) | 2019-04-08 |
| DK3290051T3 (da) | 2020-01-06 |
| CN107530426A (zh) | 2018-01-02 |
| HUE047272T2 (hu) | 2020-04-28 |
| KR102729994B1 (ko) | 2024-11-14 |
| RU2017135005A3 (es) | 2019-09-04 |
| PL3290051T3 (pl) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| TR201908291T4 (tr) | Şifrelenmiş bir tümör antijeninin ekspresyonunun arttırılmasına yönelik bir histon sap-ilmiği ve bir poli(a) sekansı veya bir poliadenilasyon sinyali içeren veya bunun için kodlama yapan nükleik asit. | |
| CO2017012454A2 (es) | Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia | |
| MX2017007256A (es) | Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer. | |
| MX2020010701A (es) | Péptidos antigénicos para la prevención y el tratamiento del cáncer. | |
| MX2019012452A (es) | Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9. | |
| MX2017011633A (es) | Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas. | |
| CU20210061A7 (es) | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| BR112017010832A2 (pt) | composições de aminoácido para o tratamento de sintomas de doença | |
| BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
| EP4253419A3 (en) | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| BR112018008840A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| MX2017013480A (es) | Composicion farmaceutica para tratar y/o prevenir el cancer. | |
| BR112017006969A2 (pt) | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno | |
| MX392412B (es) | Polipéptidos que tienen actividad inductora de inmunidad. |